AuthorsPower, Rachel F
Hynes, Brian G
Ruggiero, Nicholas J
Kiernan, Thomas J
AffiliationDepartment of Interventional Cardiology, Cork University Hospital, University College Cork School of Medicine, Cork, Ireland.
Coronary Artery Disease
Drug Therapy, Combination
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Receptors, Purinergic P2Y12
MetadataShow full item record
CitationModern antiplatelet agents in coronary artery disease. 2012, 10 (10):1261-72 Expert Rev Cardiovasc Ther
JournalExpert review of cardiovascular therapy
AbstractDual antiplatelet therapy is well recognized in the prevention of thrombotic complications of acute coronary syndrome and percutaneous coronary interventions. Despite clinical benefits of aspirin and clopidogrel therapy, a number of limitations curtail their efficacy: slow onset of action, variability in platelet inhibitory response and potential drug-drug interactions. Furthermore, the single platelet-activation pathway targeted by these agents allows continued platelet activation via other pathways, ensuring incomplete protection against ischemic events, thus, underscoring the need for alternate antiplatelet treatment strategies. A number of novel antiplatelet agents are currently in advance development and many have established superior effects on platelet inhibition, clinical outcomes and safety profile than clopidogrel in high-risk patients. The aim of this review is to provide an overview of the current status of P2Y12 receptor inhibition and PAR-1 antagonists in determining a future strategy for individualized antiplatelet therapy.